Atrovastatin-PEG3-FITC

Cat. No.: HY-134977

CAS No.: 1440755-31-6

Molecular Formula: $C_{64}H_{68}FN_5O_{12}S$

Molecular Weight: 1150.31

Target: Ras

Pathway: GPCR/G Protein

Storage: -20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (86.93 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.8693 mL	4.3467 mL	8.6933 mL
	5 mM	0.1739 mL	0.8693 mL	1.7387 mL
	10 mM	0.0869 mL	0.4347 mL	0.8693 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (2.17 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Atrovastatin-PEG3-FITC (compound S31) is a KRAS-PDEδ interaction inhibitor. Atrovastatin-PEG3-FITC acts as a ligand in fluorescence anisotropy assay[1][2].

IC_{50} & Target

KRAS-PDEδ

REFERENCES

[1]. Gunther Zimmermann, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signaling. Nature. 2013 May 30;497(7451):638-42.

[2]. Yan Jiang, et al. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors. J Med Chem. 2017 Nov 22;60(22):9400-9406.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA